NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free GCTK Stock Alerts $2.88 +0.41 (+16.63%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$2.36▼$2.9050-Day Range$1.64▼$4.5152-Week Range$0.66▼$4.95Volume21,463 shsAverage Volume35,695 shsMarket Capitalization$15.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get GlucoTrack alerts: Email Address Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About GlucoTrack Stock (NASDAQ:GCTK)GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Read More GCTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GCTK Stock News HeadlinesJune 5 at 8:30 AM | globenewswire.comGLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMay 17, 2024 | msn.comGCTK Stock Earnings: GlucoTrack Reported Results for Q1 2024May 16, 2024 | finance.yahoo.comGLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYMay 16, 2024 | globenewswire.comGLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYMay 16, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Reverse Stock SplitMay 15, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES REVERSE STOCK SPLITMay 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATIONApril 26, 2024 | investing.comGlucoTrack director Drew Sycoff buys $230k in company sharesApril 26, 2024 | msn.comNasdaq Rises 0.5%; Tesla Shares Jump After Q1 ResultsApril 25, 2024 | msn.comGlucoTrack And 2 Other Stocks Under $1 Insiders Are BuyingApril 25, 2024 | finance.yahoo.comDirector and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)April 22, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENTApril 17, 2024 | finance.yahoo.comGlucoTrack, Inc. (GCTK)April 16, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORINGApril 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMarch 13, 2024 | nz.finance.yahoo.comUK mortgage arrears rise 50% amid high interest ratesMarch 12, 2024 | globenewswire.comGLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITYFebruary 27, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Selects Cirtec Medical As Manufacturer For Its Implantable Continuous Blood Glucose MonitorFebruary 27, 2024 | globenewswire.comGLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORFebruary 13, 2024 | msn.comGlucotrack names Luis Malavé board chairFebruary 13, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORSJanuary 3, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Early Accuracy Data For Its Implantable Continuous Glucose MonitorJanuary 2, 2024 | msn.comGlucoTrack stock jumps 13% on preclinical update for glucose monitorJanuary 2, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITORDecember 1, 2023 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces 180-day Extension To Regain Compliance With Nasdaq Minimum Bid Price RequirementSee More Headlines Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-207.55% Return on Assets-151.03% Debt Debt-to-Equity Ratio0.52 Current Ratio1.31 Quick Ratio1.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book3.73Miscellaneous Outstanding Shares5,480,000Free Float4,509,000Market Cap$15.76 million OptionableNot Optionable Beta0.13 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Paul V. Goode Ph.D. (Age 55)Chief Executive Officer Comp: $225kMr. Mark Tapsak Ph.D. (Age 55)Vice President of Technology Comp: $165kMs. Drinda Benjamin (Age 48)Vice President of Marketing Mr. James P. Thrower Ph.D. (Age 54)Vice President of Engineering Comp: $230kMr. Avner Gal MBA (Age 70)MSc.EE, Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Comp: $187.39kMr. David Malka BA (Age 59)Co-Founder Comp: $191.86kMr. James S. Cardwell (Age 63)Chief Financial Officer More ExecutivesKey CompetitorsCytosorbentsNASDAQ:CTSOIceCure MedicalNASDAQ:ICCMLucid DiagnosticsNASDAQ:LUCDBeyond AirNASDAQ:XAIRHoldco Nuvo Group D.GNASDAQ:NUVOView All CompetitorsInsidersDrew SycoffBought 36,508 shares on 4/22/2024Total: $230,000.40 ($6.30/share)View All Insider Transactions GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed in 2024? GlucoTrack's stock was trading at $1.3075 at the beginning of the year. Since then, GCTK stock has increased by 119.9% and is now trading at $2.8750. View the best growth stocks for 2024 here. Are investors shorting GlucoTrack? GlucoTrack saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,600 shares, a decline of 97.9% from the April 30th total of 75,500 shares. Based on an average daily trading volume, of 41,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are short sold. View GlucoTrack's Short Interest. When is GlucoTrack's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GCTK earnings forecast. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.60) earnings per share for the quarter. When did GlucoTrack's stock split? GlucoTrack's stock reverse split on Monday, May 20th 2024. The 1-5 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GCTK) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.